M Serra

Summary

Affiliation: Istituti Ortopedici Rizzoli
Country: Italy

Publications

  1. ncbi mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts
    Marieke L Kuijjer
    Department of Pathology, Leiden University Medical Center, The Netherlands
    BMC Med Genomics 4:66. 2011
  2. ncbi Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors
    Suvi Savola
    Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki, Helsinki, Finland
    BMC Cancer 9:17. 2009
  3. ncbi Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities
    Massimo Serra
    Laboratorio di Ricerca Oncologica, Sezione di Chemioterapia, Servizio di Anatomia Patologica, Va Divisione, and Unita di Chirurgia Generale, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Clin Oncol 21:536-42. 2003
  4. ncbi Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells
    M Serra
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 15:151-60. 2004
  5. ncbi May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol
    Massimo Serra
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Int J Oncol 29:1459-68. 2006
  6. ncbi CD99 engagement: an effective therapeutic strategy for Ewing tumors
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer Res 60:5134-42. 2000
  7. ncbi P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy
    N Baldini
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, University of Bologna, Italy
    J Orthop Res 17:629-32. 1999
  8. ncbi Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Dipartimento Goidanich, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 87:328-35. 2000
  9. ncbi The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71
    M C Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, I-40136 Bologna, Italy
    Int J Oncol 27:1605-16. 2005
  10. ncbi Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells
    M C Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, I-40136 Bologna, Italy
    Int J Oncol 24:365-72. 2004

Collaborators

Detail Information

Publications47

  1. ncbi mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts
    Marieke L Kuijjer
    Department of Pathology, Leiden University Medical Center, The Netherlands
    BMC Med Genomics 4:66. 2011
    ..We aimed to investigate whether gene expression profiles of osteosarcoma cell lines and xenografts are still comparable to those of the primary tumor...
  2. ncbi Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors
    Suvi Savola
    Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki, Helsinki, Finland
    BMC Cancer 9:17. 2009
    ..Our genome-wide high-resolution analysis aspired to pinpoint genomic regions of highest interest and possible target genes in these areas...
  3. ncbi Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities
    Massimo Serra
    Laboratorio di Ricerca Oncologica, Sezione di Chemioterapia, Servizio di Anatomia Patologica, Va Divisione, and Unita di Chirurgia Generale, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Clin Oncol 21:536-42. 2003
    ..To evaluate the prognostic value of P-glycoprotein and clinicopathologic parameters in a large series of high-grade osteosarcoma (OS) patients treated at the Rizzoli Institute...
  4. ncbi Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells
    M Serra
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 15:151-60. 2004
    ..To evaluate the impact of dihydrofolate reductase (DHFR) and reduced folate carrier (RFC) genes on methotrexate (MTX) resistance in osteosarcoma cells in relation to retinoblastoma (RB1) gene status...
  5. ncbi May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol
    Massimo Serra
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Int J Oncol 29:1459-68. 2006
    ..P-glycoprotein evaluation can therefore constitute the basis for stratifying, at diagnosis, osteosarcoma patients for whom alternative treatments may be considered...
  6. ncbi CD99 engagement: an effective therapeutic strategy for Ewing tumors
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer Res 60:5134-42. 2000
    ..These results provide a novel entry site for therapeutic intervention, which may have application in the care of patients with Ewing tumor, and warrant additional studies to clarify the molecular mechanisms activated by CD99 engagement...
  7. ncbi P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy
    N Baldini
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, University of Bologna, Italy
    J Orthop Res 17:629-32. 1999
    ..Standard programs are sufficient for P-glycoprotein-negative osteosarcomas, whereas P-glycoprotein-positive tumors may benefit from the use of more intensive therapeutic approaches...
  8. ncbi Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Dipartimento Goidanich, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 87:328-35. 2000
    ..Detection of EWS/FLI-1 fusion transcripts in giant-cell tumor of bone provides a model for the study of the transforming mechanisms of the EWS/FLI-1 fusion gene in mesenchymal tumors...
  9. ncbi The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71
    M C Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, I-40136 Bologna, Italy
    Int J Oncol 27:1605-16. 2005
    ....
  10. ncbi Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells
    M C Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, I-40136 Bologna, Italy
    Int J Oncol 24:365-72. 2004
    ..Therefore, our data support the use of IFNalpha or IFNbeta in the treatment of osteosarcoma patients who overexpress P-glycoprotein in their primary tumors, and respond insufficiently to current therapeutic regimens...
  11. ncbi Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment
    G Bacci
    Section of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 18:2037-40. 2007
    ..Post 5-year follow-up for these patients was 9.7 years (5.5-29 years)...
  12. ncbi Simultaneous paired analysis of numerical chromosomal aberrations and DNA content in osteosarcoma
    M Serra
    Laboratorio di Ricerca OncologicaIstituti Ortopedici Rizzoli, Bologna, Italy
    Mod Pathol 14:710-6. 2001
    ....
  13. ncbi Murine model for skeletal metastases of Ewing's sarcoma
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Universita degli Studi di Bologna, Italy
    J Orthop Res 18:959-66. 2000
    ..This experimental model of bone metastasis of Ewing's sarcoma may be the basis for future studies aimed at understanding the pathophysiology and treatment of Ewing's sarcoma...
  14. ncbi Ewing's sarcoma family tumours. Differences in clinicopathological characteristics at presentation between localised and metastatic tumours
    G Bacci
    Istituti Ortopedici Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    J Bone Joint Surg Br 89:1229-33. 2007
    ..We concluded that in ESFT the site, the serum level of lactic dehydrogenase, fever, and the interval between the onset of symptoms and diagnosis are indicators of tumours having a particularly aggressive metastatic behaviour...
  15. ncbi Prognostic and therapeutic targets in the Ewing's family of tumors (PROTHETS)
    P Picci
    Istituti Ortopedici Rizzoli, Bologna, Italy
    Adv Exp Med Biol 587:1-12. 2006
    ..LSHC-CT-2004-503036. The research will concentrate on translating the knowledge being created by genomics and other fields of basic research into applications that improve clinical practice and public health...
  16. ncbi Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma
    P Ragazzini
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 19:401-11. 2004
    ..These two seem to have a more similar behavior than anaplastic and classic embryonal that are classified in the same subtype...
  17. ncbi Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells
    R Strammiello
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Horm Metab Res 35:675-84. 2003
    ..Taken together, these findings add a new activity to the IGF-I repertoire in ES and highlight how disruption of IGF-IR functions may constitute an effective tool for the control of neovascularization in this tumor...
  18. ncbi Malignant fibrous histiocytoma of bone: analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry
    Maija Tarkkanen
    Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, P O Box 21, FI 00014 Helsinki, Finland
    Eur J Cancer 42:1172-80. 2006
    ..Finally, the findings of the present study reflect well the high malignancy and aggressive nature of bone MFH...
  19. ncbi No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma
    Gaetano Bacci
    Chemotherapy Research of the Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Anticancer Drugs 17:411-5. 2006
    ..Thus, increasing the dose of MTX increases the MTX serum peaks, but does not correlate with the histologic response of the tumor...
  20. ncbi Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Surg Oncol 96:118-23. 2007
    ..Indications and contraindications for limb salvage versus amputation for local treatment of osteosarcoma of the extremity are still controversial...
  21. ncbi Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999
    Gaetano Bacci
    Section of Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Orthop 78:377-84. 2007
    ....
  22. ncbi Prognostic value of CCN3 in osteosarcoma
    Bernard Perbal
    Laboratorio di Ricerca Oncologica and Laboratorio di Rigenerazione Tissutale Ossea, Istituti Ortopedici Rizzoli, Bologna, Italy
    Clin Cancer Res 14:701-9. 2008
    ..We assessed the prognostic value of CCN1, CCN2, and CCN3 genes, involved in fundamental biological processes...
  23. ncbi Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling
    Lara Cantiani
    Laboratory of Oncology Research, Rizzoli Orthopaedic Institute, Italy
    Cancer Res 67:7675-85. 2007
    ..These data strengthen the rationale to target c-Src family kinases and/or Met receptor to improve the extremely poor prognosis of metastatic osteosarcoma...
  24. ncbi Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma
    Michela Pasello
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer Res 68:6661-8. 2008
    ....
  25. ncbi Prognostic value of P-glycoprotein in high-grade osteosarcoma
    Massimo Serra
    J Clin Oncol 25:4858-60; author reply 4860-1. 2007
  26. ncbi P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2
    Elisa Zuffa
    Department of Radiation Oncology Luigi Galvani, University of Bologna Medical School, Bologna, Italy
    Int J Radiat Biol 84:591-601. 2008
    ..To investigate the impact of TP53 (tumor protein 53, p53) on genomic stability of osteosarcoma (OS)...
  27. ncbi Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma
    Gianluca Brusa
    Istituto di Ematologia e Oncologia Medica Lorenzo e Ariosto Serágnoli, Università di Bologna Medical School, 40138 Bologna, Italy
    Oncol Rep 18:1427-34. 2007
    ..Immunohistochemistry confirmed aCGH results and distinguished the distribution of either amplified or deleted gene products in neoplastic Reed Sternberg (RS) cells and non-neoplastic lymph node components...
  28. ncbi Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma
    I Scionti
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 19:1500-8. 2008
    ..C-MYC and DHFR protein levels at diagnosis were assessed by immunohistochemistry on series of patients treated with either a MTX-based protocol (IOR/OS-1; 72 patients) or with a standard four-drug regimen (ISG/SSG 1; 61 patients)...
  29. ncbi CD99 acts as an oncosuppressor in osteosarcoma
    Maria Cristina Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, 40136 Italy
    Mol Biol Cell 17:1910-21. 2006
    ..The findings point to an antioncogenic role for CD99 in osteosarcoma, likely through the regulation of caveolin-1 and inhibition of c-Src kinase activity...
  30. ncbi Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone
    Claudia Maria Hattinger
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Eur J Cell Biol 83:483-91. 2004
    ..Moreover, these findings suggest the possible presence of an autocrine loop in FS of bone, which might be taken into account for planning innovative therapeutic strategies for patients unresponsive to conventional treatments...
  31. ncbi Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
    Leonardo A Meza-Zepeda
    Department of Tumour Biology, The Norwegian Radium Hospital, Montebello N 0310, Oslo, Norway
    Oncogene 21:2261-9. 2002
    ..Quite likely, the different genes may give selective advantages to different subsets of tumours...
  32. ncbi Preferential expression of RB1-inducible coiled-coil 1 in terminal differentiated musculoskeletal cells
    Tokuhiro Chano
    Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan
    Am J Pathol 161:359-64. 2002
    ....
  33. ncbi Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 101:11-6. 2002
    ....
  34. ncbi Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Clin Cancer Res 8:3893-903. 2002
    ..In this study, we analyzed the preclinical effectiveness of this drug in osteosarcoma and Ewing's sarcoma...
  35. ncbi Identification of markers of possible prognostic value in 57 giant cell tumors of bone
    Gabriella Gamberi
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, I 40136 Bologna, Italy
    Oncol Rep 10:351-6. 2003
    ..Therefore, the evaluation of the expression levels of these proteins at the time of diagnosis may be taken into consideration for a classification of GCT into categories characterized by a different risk to relapse...
  36. ncbi C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica and Servicio di Anatomia Patologica, Istituti Ortopedici Rizzoli, Via Di Barbiano 1 10, 40136 Bologna, Italy
    J Clin Oncol 21:1952-60. 2003
    ..Autocrine/paracrine stimulation of c-kit has been recently observed in Ewing's sarcoma (ES) cell lines. In this study, we tested the prognostic and therapeutic role of the receptor in this tumor...
  37. ncbi Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques
    Claudia M Hattinger
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Eur J Cell Biol 82:483-93. 2003
    ..These data demonstrate that genetic analyses with complementary techniques are helpful for the identification of new candidate genes, which might be considered for an early identification of MTX unresponsive tumors...
  38. ncbi Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects
    Stefania Benini
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 108:358-66. 2004
    ..Our findings therefore identify MAPK pathway as a promising target for pharmacologic intervention in ES...
  39. ncbi Differentially expressed genes in multidrug resistant variants of U-2 OS human osteosarcoma cells
    Tokuhiro Chano
    Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Tsukinowa cho, Seta, Otsu, Shiga 520 2192, Japan
    Oncol Rep 11:1257-63. 2004
    ..Molecular and biological characterization of these genes will yield further insight into the features between MDR and tumor progression in human osteosarcomas...
  40. ncbi Gene amplifications in osteosarcoma-CGH microarray analysis
    Jassu Atiye
    Departments of Pathology and Medical Genetics, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Genes Chromosomes Cancer 42:158-63. 2005
    ..Details (www.helsinki.fi/cmg) of the amplified genes in each amplicon provide valuable raw data for further in silico studies...
  41. ncbi The expression of ccn3(nov) gene in musculoskeletal tumors
    Maria Cristina Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Am J Pathol 160:849-59. 2002
    ..Further studies will help to clarify the biological role of this protein in musculoskeletal neoplasms...
  42. ncbi In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type
    Stefania Benini
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Oncogene 24:4349-61. 2005
    ..However, the underlying molecular mechanisms appear to be different, further highlighting the importance of the cellular context in the regulation of function of CCN proteins...
  43. ncbi Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors
    Katia Scotlandi
    Laboratory of Oncologic Research, Orthopaedic Rizzoli Institute, Bologna, Italy
    Cancer Res 65:3868-76. 2005
    ..For the broadest applicability and best efficacy in sarcomas, NVP-AEW541 may be combined with vincristine, actinomycin D, and ifosfamide, three major drugs in the treatment of sarcomas...
  44. ncbi Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via Di Barbiano 1 10, 40136 Bologna, Italy
    Eur J Cancer 41:1349-61. 2005
    ..Therefore, the therapeutic potential of trastuzumab in these neoplasms may be better exploited in combined treatments with anti-IGF-IR approaches...
  45. ncbi 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients
    Michela Pasello
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy
    Eur J Cancer 41:2184-95. 2005
    ....
  46. ncbi Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer Gene Ther 9:296-307. 2002
    ..These results indicate that inhibiting IGF-IR by antisense strategies may be relevant to the clinical treatment of ES patients by reducing the malignant potential of these cells and enhancing the effectiveness of chemotherapy...
  47. ncbi Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors
    Fernanda Martini
    Department of Morphology and Embryology, Section of Histology and Embryology, University of Ferrara, Ferrara, Italy
    Cancer 94:1037-48. 2002
    ....